Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Show all 20 references

Sorted by citations

Items 201–300 of 1,001

Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles
Ladewig, K., Niebert, M., Xu, Z. P., Gray, P. P., & Lu, G. Q. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.058 · Cited by 188
Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect
Veldhoen, S., Laufer, S. D., Trampe, A., & Restle, T. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl941 · Cited by 191
Targeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 190
Delivery of oligonucleotides with lipid nanoparticles
Wang, Y., Miao, L., Satterlee, A., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.007 · Cited by 184
“pH-sensitive ionizable lipids have therefore been developed to accommodate the need to deliver siRNAs [24, 84-86] and ONs [69, 82, 87].”
Background
Self-Amplifying mRNA Vaccines
Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 181
An influenza virus-inspired polymer system for the timed release of siRNA
Truong, N. P., Gu, W., Prasadam, I., Jia, Z., Crawford, R., Xiao, Y., & Monteiro, M. J. (2013) · Nature Communications · doi:10.1038/ncomms2905 · Cited by 180
Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells
Basha, G., Novobrantseva, T. I., Rosin, N. L., Tam, Y. Y. C., Hafez, I. M., Wong, M., Sugo, T., Ruda, V. M., Qin, J., Klebanov, B., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.190 · Cited by 182
Synthesis and Biological Evaluation of a Bioresponsive and Endosomolytic siRNA−Polymer Conjugate
Meyer, M., Dohmen, C., Philipp, A. B., Kiener, D., Maiwald, G., Scheu, C., Ogris, M., & Wagner, E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp9000124 · Cited by 180
Liposome-based delivery of biological drugs
Magar, K. T., Boafo, G. F., Li, X., Chen, Z., & He, W. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.08.020 · Cited by 189
Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo
Sato, Y., Hashiba, K., Sasaki, K., Maeki, M., Tokeshi, M., & Harashima, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.001 · Cited by 183
Nanovector delivery of siRNA for cancer therapy
Shen, H., Sun, T., & Mauro Ferrari, B. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.22 · Cited by 176
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Hsu, S., Yu, B., Wang, X., Lu, Y., Schmidt, C. R., Lee, R. J., Lee, L. J., Jacob, S. T., & Ghoshal, K. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.05.007 · Cited by 185
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
“[54] first successfully demonstrated that the application of LNPs for the systemic delivery of siRNA could downregulate gene expression in non-human primates, thereby knocking down serum apolipoprotein B levels.”
Background
RNAa Is Conserved in Mammalian Cells
Huang, V., Qin, Y., Wang, J., Wang, X., Place, R. F., Lin, G., Lue, T. F., & Li, L.-C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008848 · Cited by 174
“In fact, non-human primate disease models are often used to test preclinical safety and efficacy of vector-based gene therapy [10] and for testing systematic delivery of RNAi-based therapeutics [11,12,13].”
Background
MicroRNA: an Emerging Therapeutic Target and Intervention Tool
Liu, Z., Sall, A., & Yang, D. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9060978 · Cited by 175
“Besides nonspecific agent like cationic liposome and cholesterol [88, 89], novel nanotechnology-based conjungation of bacterial phage packaging RNA with therapeutic molecules, receptor binding RNA aptamers, antibody-protamine, etc, have been”
Background
Macrophage inflammatory protein-1α mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1β up-regulation
Kiguchi, N., Maeda, T., Kobayashi, Y., Fukazawa, Y., & Kishioka, S. (2010) · Pain · doi:10.1016/j.pain.2010.02.025 · Cited by 175
“Generally, siRNA shows specific gene silencing, and the effect is dose-dependent [50].”
MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15+/CD133+ Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma
Antonellis, P. D., Medaglia, C., Cusanelli, E., Andolfo, I., Liguori, L., Vita, G. D., Carotenuto, M., Bello, A. M., Formiggini, F., Galeone, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024584 · Cited by 174
“data in non-human-primate trials [42].”
Proton Sponge Trick for pH-Sensitive Disassembly of Polyethylenimine-Based siRNA Delivery Systems
Creusat, G., Rinaldi, A., Weiss, É., Elbaghdadi, R., Rémy, J.-S., Mulherkar, R., & Zuber, G. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100010k · Cited by 171
Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I
Kim, S. I., Shin, D., Choi, T. H., Lee, J. C., Cheon, G. J., Kim, K.-Y., Park, M., & Kim, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300168 · Cited by 169
RNAi-based nanomedicines for targeted personalized therapy
Daka, A., & Peer, D. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.014 · Cited by 169
RNA Interference and Cancer Therapy
Wang, Z., Rao, D. D., Senzer, N. N., & Nemunaitis, J. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0604-5 · Cited by 171
Small heat shock proteins in cancer therapy and prognosis
Zoubeidi, A., & Gleave, M. E. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.010 · Cited by 166
Efficient siRNA Delivery with Non-viral Polymeric Vehicles
Kim, W. J., & Kim, S. W. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9774-1 · Cited by 166
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain
Rungta, R. L., Choi, H. B., Lin, P. J., Ko, R. W., Ashby, D., Nair, J., Manoharan, M., Cullis, P. R., & MacVicar, B. A. (2013) · Molecular Therapy—Nucleic Acids · doi:10.1038/mtna.2013.65 · Cited by 165
Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis
Laroui, H., Viennois, É., Xiao, B., Canup, B. S. B., Geem, D., Denning, T. L., & Merlin, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.046 · Cited by 163
Cationic Bovine Serum Albumin Based Self‐Assembled Nanoparticles as siRNA Delivery Vector for Treating Lung Metastatic Cancer
Han, J., Wang, Q. L., Zhang, Z., Gong, T., & Sun, X. (2013) · Small · doi:10.1002/smll.201301992 · Cited by 166
Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation☆
Akita, H., Kogure, K., Moriguchi, R., Nakamura, Y., Higashi, T., Nakamura, T., Serada, S., Fujimoto, M., Naka, T., & Futaki, S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.012 · Cited by 164
Impact of tumor‐specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA‐containing nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21668 · Cited by 164
LABORATORY PRIMATE NEWSLETTER
Schrier, J. E., Harper, J. S., Hankinson, G. J., Hulsebos, L., Povar, M. L., Mathiesen, E., & Schrier, A. M. (2009) · Cited by 166
The Guideline of the Design and Validation of MiRNA Mimics
Wang, Z. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-863-8_15 · Cited by 163
NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA
Jiang, S., Zhang, Y., Lim, K. M., Sim, E. K. W., & Ye, L. (2009) · Nanotechnology · doi:10.1088/0957-4484/20/15/155101 · Cited by 159
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
“Lipid nanoparticles (LNPs) are the leading delivery systems for enabling the therapeutic potential of siRNA for systemic applications (Semple et al., 2010; Zimmermann et al., 2006).”
Chemical modifications of nucleic acid drugs and their delivery systems for gene‐based therapy
Chen, C., Yang, Z., & Tang, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21479 · Cited by 164
Lipidic Systems for In Vivo siRNA Delivery
Wu, S. Y., & McMillan, N. A. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9140-1 · Cited by 160
“The success of this delivery system led to the first systemic siRNA delivery study in nonhuman primates in 2006 ( 54 ).”
Background
Heart failure with preserved ejection fraction in the elderly: scope of the problem
Upadhya, B., Taffet, G. E., Cheng, C. P., & Kitzman, D. W. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.02.025 · Cited by 160
Acid-Degradable Cationic Dextran Particles for the Delivery of siRNA Therapeutics
Cohen, J. L., Schubert, S., Wich, P. R., Cui, L., Cohen, J. A., Mynar, J. L., & Fréchet, J. M. J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100542r · Cited by 158
Dendrimers for siRNA Delivery
Biswas, S., & Torchilin, V. P. (2013) · Pharmaceuticals · doi:10.3390/ph6020161 · Cited by 158
“However, the small molecule-mediated drug action may not be achieved if the disease-related protein has a conformation that is not accessible to small molecules, which is then referred to as a “non-druggable” target [9,47].”
Background
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing
Bartlett, D. W., & Davis, M. E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21285 · Cited by 154
Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery
Raouane, M., Desmaële, D., Urbinati, G., Massaad-Massade, L., & Couvreur, P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200422w · Cited by 161
siRNA based drug design, quality, delivery and clinical translation
Subhan, M. A., & Torchilin, V. P. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102239 · Cited by 152
Targeted Delivery Systems for Oligonucleotide Therapeutics
Yu, B., Zhao, X., Lee, L. J., & Lee, R. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9096-1 · Cited by 158
“, stable nucleic acid lipid particles (3,4) to facilitate long systemic circulation time and improved efficiency for in vivo delivery.”
Background
Lipids and polymers in pharmaceutical technology: Lifelong companions
Siepmann, J., Faham, A., Clas, S., Boyd, B. J., Jannin, V., Bernkop‐Schnürch, A., Zhao, H., Lecommandoux, S., Evans, J. C., Allen, C. J., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.080 · Cited by 155
Nanoparticle Therapy for Vascular Diseases
Flores, A. M., Ye, J., Jarr, K.-U., Hosseini-Nassab, N., Smith, B. R., & Leeper, N. J. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311569 · Cited by 155
“31,32 The opportunity to target apoB is particularly exciting given genetic and epidemiological studies that suggest the clinical benefit of lowering LDL may depend on a corresponding reduction in apoB levels.”
The protective and destructive roles played by molecular chaperones during ERAD (endoplasmic-reticulum-associated degradation)
Brodsky, J. L. (2007) · Biochemical Journal · doi:10.1042/bj20061890 · Cited by 149
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie · doi:10.1002/ange.201203263 · Cited by 150
Self-citation
Therapeutic Potential of Splice-Switching Oligonucleotides
Bauman, J. A., Jearawiriyapaisarn, N., & Kole, R. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0161 · Cited by 150
Oligonucleotide Conjugates for Therapeutic Applications
Winkler, J. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.47 · Cited by 149
Special delivery: targeted therapy with small RNAs
Peer, D., & Lieberman, J. (2011) · Gene Therapy · doi:10.1038/gt.2011.56 · Cited by 152
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?
Grimm, D., & Kay, M. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci34129 · Cited by 151
Short Interfering RNA against Transient Receptor Potential Vanilloid 1 Attenuates Cisplatin-Induced Hearing Loss in the Rat
Mukherjea, D., Jajoo, S., Whitworth, C. A., Bunch, J. R., Turner, J. G., Rybak, L. P., & Ramkumar, V. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1307-08.2008 · Cited by 147
“Others have observed that siRNA against different targets, such as the ApoB gene (Zimmermann et al., 2006), produced longer term reductions in these target proteins, compared with conventional drugs which target these proteins, and with minimal side effects.”
Background
Functional Delivery of siRNA in Mice Using Dendriworms
Agrawal, A., Min, D., Singh, N., Zhu, H., Birjiniuk, A., von Maltzahn, G., Harris, T. J., Xing, D., Woolfenden, S. D., Sharp, P. A., et al. (2009) · ACS Nano · doi:10.1021/nn900201e · Cited by 147
“siRNA backbone or end-groups modifications that impart siRNA serum stability and improve cell membrane penetration have been used successfully to knockdown genes in vivo.(10,11) Protamine-antibody fusions have also been used to successfully transfect HIV infected T cells.”
Method
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway
John, M., Constien, R., Akinc, A., Goldberg, M. S., Moon, Y.-A., Spranger, M., Hadwiger, P., Soutschek, J., Vornlocher, H., Manoharan, M., et al. (2007) · Nature · doi:10.1038/nature06179 · Cited by 145
MicroRNAs and cell differentiation in mammalian development
Song, L., & Tuan, R. S. (2006) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20070 · Cited by 145
Advances in Drug Delivery
Timko, B. P., Whitehead, K. A., Gao, W., Kohane, D. S., Farokhzad, O. C., Anderson, D. G., & Langer, R. (2011) · Annual Review of Materials Research · doi:10.1146/annurev-matsci-062910-100359 · Cited by 143
5′‐( E )‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates
Parmar, R. G., Willoughby, J. L. S., Liu, J., Foster, D. J., Brigham, B., Theile, C. S., Charissé, K., Akinc, A., Guidry, E. N., Pei, Y., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201600130 · Cited by 146
siRNA Delivery with Chitosan: Influence of Chitosan Molecular Weight, Degree of Deacetylation, and Amine to Phosphate Ratio on in Vitro Silencing Efficiency, Hemocompatibility, Biodistribution, and in Vivo Efficacy
Alameh, M., Lavertu, M., Tran‐Khanh, N., Chang, C., Lesage, F., Bail, M., Darras, V., Chevrier, A., & Buschmann, M. D. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01297 · Cited by 142
Liposomal Nanomedicines: An Emerging Field
Fenske, D. B., Chonn, A., & Cullis, P. R. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310960 · Cited by 144
Delivery strategies and potential targets for siRNA in major cancer types
Lee, S. J., Kim, M. J., Kwon, I. C., & Roberts, T. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.010 · Cited by 146
Heme Oxygenase-1 Is an Anti-Inflammatory Host Factor that Promotes Murine Plasmodium Liver Infection
Epiphânio, S., Mikolajczak, S. A., Gonçalves, L. A., Pamplona, A., Portugal, S., Albuquerque, S., Goldberg, M. S., Rebelo, S., Anderson, D. G., Akinc, A., et al. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.04.003 · Cited by 141
Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications
Barba, A. A., Bochicchio, S., Dalmoro, A., & Lamberti, G. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080360 · Cited by 147
“In the light of the positive preclinical results [100] a phase I clinical trial has been initiated (NCT 00927459, 2009, “Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol”).”
Background
siRNA applications in nanomedicine
Tokatlian, T., & Segura, T. (2010) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.81 · Cited by 138
Applications of RNA Interference in Mammalian Systems
Martin, S. E., & Caplen, N. J. (2007) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092424 · Cited by 140
Promise and Challenge of RNA Interference–Based Therapy for Cancer
Petrocca, F., & Lieberman, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6287 · Cited by 138
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
Novobrantseva, T. I., Borodovsky, A., Wong, J., Klebanov, B., Zafari, M. R., Yucius, K., Querbes, W., Ge, P., Ruda, V. M., Milstein, S., et al. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2011.3 · Cited by 137
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
Shepherd, S. J., Han, X., Mukalel, A. J., El-Mayta, R. D., Thatte, A. S., Wu, J., Padilla, M. S., Alameh, M., Srikumar, N., Lee, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303567120 · Cited by 146
“) (D) Comparison of the LNP production rate for the SCALAR platform (Top; blue), T- junction mixing (37, 38) (Center; purple), and a single herringbone micromixer chip (23, 24) (Bottom; green) in terms of volumetric throughput (Bottom x axis) and mRNA vaccine doses per hour (Top x axis) assuming that 1 mRNA vaccine do…”
An RNA Alternative to Human Transferrin: A New Tool for Targeting Human Cells
Wilner, S. E., Wengerter, B. C., Maier, K. E., Magalhães, M. D. L. B., del Amo, D. S., Pai, S., Opazo, F., Rizzoli, S. O., Yan, A. C., & Levy, M. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.14 · Cited by 138
Nanomaterials for Therapeutic RNA Delivery
Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 139
“Meanwhile, DLin-MC3-DMA or its analogs, together with phospholipid, polyethylene glycol (PEG) lipid, and cholesterol (Figures 4D–4F), were formulated into specialized liposomes (namely stable nucleic acid-lipid particle [SNALP]), which yielded potent and persistent in vivo gene-silencing activity after systemic delive…”
Background
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 143
Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice
Sato, A., Takagi, M., Shimamoto, A., Kawakami, S., & Hashida, M. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.010 · Cited by 134
Lipid-Based Nanoparticles in The Systemic Delivery of siRNA
Lin, Q., Chen, J., Zhang, Z., & Zheng, G. (2013) · Nanomedicine · doi:10.2217/nnm.13.192 · Cited by 133
Supramolecular assemblies in functional siRNA delivery: Where do we stand?
Aliabadi, H. M., Landry, B. K., Sun, C., Tang, T., & Uludağ, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.079 · Cited by 135
“SNAPL formulations of siRNA has been successfully employed for Apolipoprotein B (ApoB) silencing in cynomolgus monkeys [40] and for polo-like kinase 1 (PLK1) silencing in subcutaneous tumors in mice (w75% reduction in size) [41].”
BackgroundMethod
Oligonucleotide therapeutic approaches for Huntington disease
Sah, D. W. Y., & D, N. A. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45130 · Cited by 133
“) (98) Dosing paradigm Chronic infusion Bolus injection(s) (62, 63, 65, 66) Chronic infusion Control over drug dose High Low-medium High Cellular site of action Cytoplasm Nucleus cytoplasm Nucleus cytoplasm Gene specificity High High High Allele specificity through SNP targeting High (13, 14) Potentially high Low-medi…”
Background
Cellular uptake and intracellular trafficking of oligonucleotides
Juliano, R. L., & Carver, K. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.005 · Cited by 138
“While initial emphasis was on cholesterol conjugates that would affiliate with plasma lipoproteins [91], more recently ligands that can target specific receptors including aptamers [92, 93], small organic molecules [94], peptides [95, 96], and carbohydrates [97, 98] have all been explored.”
Background
Detection and treatment of atherosclerosis using nanoparticles
Zhang, J., Zu, Y., Dhanasekara, C. S., Li, J., Wu, D., Fan, Z., & Wang, S. F. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1412 · Cited by 132
Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics
Ewert, K. K., Scodeller, P., Simón‐Gracia, L., Steffes, V. M., Wonder, E. A., Teesalu, T., & Safinya, C. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091365 · Cited by 128
“Building on decades of work on both the lipid vector [72,74,75] and the mRNA payload [70], the vaccines developed by Pfizer/BioNTech [76–78] and Moderna [79,80] became the first vaccines approved against COVID-19 in December 2020.”
Current Status and Future Perspectives on MRNA Drug Manufacturing
Webb, C., Ip, S. Y., Bathula, N. V., Popova, P. G., Soriano, S. K. V., Ly, B.-H., Eryilmaz, B., Huu, V. A. N., Broadhead, R., Rabel, M., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00010 · Cited by 134
Microfluidic Manufacture of Lipid-Based Nanomedicines
Osouli-Bostanabad, K., Puliga, S., Serrano, D. R., Bucchi, A., Halbert, G., & Lalatsa, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091940 · Cited by 137
Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics
Leong, E. W. X., & Ge, R. (2022) · Biomedicines · doi:10.3390/biomedicines10092179 · Cited by 134
“Liposomes have also been applied in nucleic acid delivery where they first demonstrated their promise in siRNA-mediated liver gene silencing in non-human primates [33,47].”
Background
Safety profile of RNAi nanomedicines
Barros, S. A., & Gollob, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.007 · Cited by 125
Self-degradable lipid-like materials based on “hydrolysis accelerated by the intra-particle enrichment of reactant (HyPER)” for messenger RNA delivery
Tanaka, H., Takahashi, T., Konishi, M., Takata, N., Gomi, M., Shirane, D., Miyama, R., Hagiwara, S., Yamasaki, Y., Sakurai, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910575 · Cited by 126
Controlling HBV Replication in Vivo by Intravenous Administration of Triggered PEGylated siRNA-Nanoparticles
Carmona, S., Jorgensen, M. R., Kolli, S., Crowther, C. E., Salazar, F. H., Marion, P. L., Fujino, M., Natori, Y., Thanou, M., Arbuthnot, P. B., et al. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800157x · Cited by 127
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
Morille, M., Montier, T., Legras, P., Carmoy, N., Brodin, P. M., Pitard, B., Benoît, J., & Passirani, C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.044 · Cited by 137
Targeted Systemic Delivery of a Therapeutic siRNA with a Multifunctional Carrier Controls Tumor Proliferation in Mice
Wang, X.-L., Xu, R., Wu, X., Gillespie, D. L., Jensen, R. L., & Lu, Z. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800192d · Cited by 125
Epigenetics and MicroRNAs
Sætrom, P., Snøve, O., & Rossi, J. J. (2007) · Pediatric Research · doi:10.1203/pdr.0b013e318045760e · Cited by 128
Aptamer-targeted cell-specific RNA interference
Zhou, J., & Rossi, J. J. (2010) · Silence · doi:10.1186/1758-907x-1-4 · Cited by 128
“Alternatively, siRNAs have also been non-covalently assembled with active recognition moieties and delivery vehicles as multifunctional targeting delivery systems, such as folate conjugated dendrimer [21], folate-conjugated phage RNAs [22-24], transferrin modified polymer/liposomes [25-28], peptide-based nanovectors […”
Background
RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice
Yasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J. D., New, M. I., Liebow, A., Fitzgerald, K. J., Querbes, W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406228111 · Cited by 124
Surface‐Modified LPD Nanoparticles for Tumor Targeting
Li, S., & Huang, L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.001 · Cited by 123
Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages
Huang, X., Chuang, L. I. U., Kong, N., Xiao, Y., Yurdagul, A., Tabas, I. A., & Tao, W. (2022) · Nature Protocols · doi:10.1038/s41596-021-00665-4 · Cited by 126
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo
Aigner, A. M. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0984-y · Cited by 123
Matrix metalloproteinase 2-responsive micelle for siRNA delivery
Wang, H., Yang, X., Sun, C., Mao, C., Zhu, Y., & Wang, J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.050 · Cited by 124
Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment
Costa, P. M., Cardoso, A. L., Mendonça, L. S., Serani, A., Custódia, C., Conceição, M., Simões, S., Moreira, J. N., de Almeida, L. P., & de Lima, M. C. P. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.30 · Cited by 126
Autophagy-mediated longevity is modulated by lipoprotein biogenesis
Seah, N., Filho, C. D. D. M., Petrashen, A. P., Henderson, H. R., Laguer, J., Gonzalez, J., Dillin, A. G., Hansen, M., & Lapierre, L. R. (2015) · Autophagy · doi:10.1080/15548627.2015.1127464 · Cited by 118
“Notably, use of specific RNAi to silence APOB gene expression in primates results in significant reduction in serum APOB.(72) As lipid met-”
Maintaining the silence: reflections on long-term RNAi
Raemdonck, K., Vandenbroucke, R. E., Demeester, J., Sanders, N. N., & Smedt, S. C. D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.008 · Cited by 124
“A more recent report, using SNALP technology to deliver anti-ApoB siRNA in cynomolgus monkeys, describes marked reduction in plasma ApoB protein levels for as long as 11 days after a single i.v. injection (2.5 mg/kg) [85] .”
MethodInfluential
Brothers in Arms
Bhindi, R., Fahmy, R. G., Lowe, H. C., Chesterman, C. N., Dass, C. R., Cairns, M. J., Saravolac, E. G., Sun, L., & Khachigian, L. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070120 · Cited by 121
Engineering Nanocarriers for siRNA Delivery
Tan, S. J., Kiatwuthinon, P., Roh, Y. H., Kahn, J. S., & Luo, D. (2011) · Small · doi:10.1002/smll.201001389 · Cited by 119
Nanoparticles in the diagnosis and treatment of vascular aging and related diseases
Xu, H., Li, S., & Liu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01082-z · Cited by 130
“These anti-atherosclerotic effects were observed 24-h after injection and sustained for 11 days at the highest dose.(485) Additionally, nanoparticles-delivered miRNAs and anti-miRNAs, such as anti-miRNA-712, miRNA-206, miRNA-223, miRNA-155, miRNA-146a, miRNA-181b, and miRNA-145, are promising therapeutic approaches fo…”
Background
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines
Nakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
mRNA turnover rate limits siRNA and microRNA efficacy
Larsson, E., Sander, C., & Marks, D. S. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.89 · Cited by 120
“A destabilizing (AUUU)7 multimer element (ARE) (Zubiaga et al, 1995) was cloned into the 30 UTR of the pEZX-MT01 SV40-firefly luciferase reporter vector (Genecopoeia).”
MethodInfluential
MicroRNAs in Heart Failure
Melman, Y. F., Shah, R. V., & Das, S. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000266 · Cited by 122
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma
Martino, M. T. D., Campani, V., Misso, G., Cantafio, M. E. G., Gullà, A., Foresta, U., Guzzi, P. H., Castellano, M., Grimaldi, A., Gigantino, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090005 · Cited by 121
“SNALPs have been successfully proposed to deliver small interfering RNAs in non-human primates [7] and clinical trials are currently ongoing.”
Background

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks